Summary of clinical trials of influenza virus vaccines in adults
- PMID: 606797
- DOI: 10.1093/infdis/136.supplement_3.s722
Summary of clinical trials of influenza virus vaccines in adults
Abstract
Trials in approximately 3,900 adults were conducted with influenza A/New Jersey/76, A/Victoria/75, and B/Hong Kong/72 virus vaccines. Subjects were observed following a standard protocol, and serologic testing was performed in a single laboratory. The data indicate that prior experience of the population with earlier influenza viruses ("priming") is a determinant in response to vaccination. Thus, participants older than 25 years showed good serologic response following a single inoculation of A/New Jersey/76 virus, while younger persons responded poorly. Serological responses to A/Victoria/75 and B/Hong Kong/72 viruses were, in contrast, equally good in the younger and older adults. Whole-virus vaccines were measurably more reactive than split-virus vaccines, a finding more easily discernined in unprimed populations. In the unprimed persons, a single dose of split-virus vaccine was less immunogenic than a single dose of whole-virus vaccine. The presence of preexisting antibodies appeared to reduce systemic reactivity. For adequate immunization of a totally unprimed population, a single relatively large and reactive dose of whole-virus vaccine or two, properly spaced, smaller nonreactive doses of either whole-virus vaccine or split-virus vaccine would be required.
Similar articles
-
Serologic responses and systemic reactions in adults after vaccination with bivalent A/Victoria/75-A/New Jersey/76 and monovalent B/Hong Kong/72 influenza vaccines.J Infect Dis. 1977 Dec;136 Suppl:S507-17. doi: 10.1093/infdis/136.supplement_3.s507. J Infect Dis. 1977. PMID: 342623 Clinical Trial.
-
Correlation of laboratory studies with clinical responses to A/New Jersey influenza vaccines.J Infect Dis. 1977 Dec;136 Suppl:S397-406. doi: 10.1093/infdis/136.supplement_3.s397. J Infect Dis. 1977. PMID: 606763
-
Clinical trials with inactivated monovalent (A/New Jersey/76) and bivalent (A/New Jersey/76-A/Victoria/75) influenza vaccines in Los Angeles children.J Infect Dis. 1977 Dec;136 Suppl:S661-4. doi: 10.1093/infdis/136.supplement_3.s661. J Infect Dis. 1977. PMID: 342631 Clinical Trial.
-
Clinical trials of bivalent influenza A/New Jersey/76-A/Victoria/75 vaccines in the elderly.J Infect Dis. 1977 Dec;136 Suppl:S518-25. doi: 10.1093/infdis/136.supplement_3.s518. J Infect Dis. 1977. PMID: 342624 Clinical Trial.
-
Single-dose trials of monovalent A/New Jersey/76 (Hsw1N1) influenza virus vaccine in children in Durham, North Carolina.J Infect Dis. 1977 Dec;136 Suppl:S575-8. doi: 10.1093/infdis/136.supplement_3.s575. J Infect Dis. 1977. PMID: 606774 Clinical Trial.
Cited by
-
Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets.PLoS Med. 2006 Sep;3(9):e360. doi: 10.1371/journal.pmed.0030360. PLoS Med. 2006. PMID: 16968127 Free PMC article.
-
Safety and immunogenicity of influenza whole inactivated virus vaccines: A phase I randomized clinical trial.Hum Vaccin Immunother. 2015;11(4):983-90. doi: 10.1080/21645515.2015.1012004. Hum Vaccin Immunother. 2015. PMID: 25751506 Free PMC article. Clinical Trial.
-
Developing vaccines against pandemic influenza.Philos Trans R Soc Lond B Biol Sci. 2001 Dec 29;356(1416):1953-60. doi: 10.1098/rstb.2001.0981. Philos Trans R Soc Lond B Biol Sci. 2001. PMID: 11779397 Free PMC article.
-
Role of Multivalency and Antigenic Threshold in Generating Protective Antibody Responses.Front Immunol. 2019 May 1;10:956. doi: 10.3389/fimmu.2019.00956. eCollection 2019. Front Immunol. 2019. PMID: 31118935 Free PMC article. Review.
-
Immunogenicity of influenza A(H1N1)pdm09 vaccine in patients with diabetes mellitus: with special reference to age, body mass index, and HbA1c.Hum Vaccin Immunother. 2014;10(5):1187-94. doi: 10.4161/hv.28252. Epub 2014 Apr 9. Hum Vaccin Immunother. 2014. PMID: 24717236 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical